Navigation Links
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
Date:3/10/2008

GENEVA, Switzerland, March 10 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced that ANAVEX 7-1037 has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies. The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare type of melanoma (skin cancer) that is difficult to treat.

In comparative pre-clinical studies, ANAVEX 7-1037 reduced tumor growth by 69% with minimal side effects. Significantly, Dacarbazine, a currently available chemotherapy drug used to treat melanoma and other types of cancer, was found to be completely inactive in the same tests. ANAVEX 7-1037 is the company's lead drug candidate for the treatment of a number of cancers, including that of the breast, colon, prostate and melanoma. It exhibits a high safety profile and disease-modifying potential.

"These results further confirm the potent, anti-cancer activity and chemotherapeutic potential of ANAVEX 7-1037, even in cancers that are difficult to treat," said Dr. Kontzalis, Chief Executive Officer for ANAVEX. "We remain committed to developing first-class, cancer-fighting therapeutics based on our SIGMACEPTOR(TM) Discovery Platform, which utilizes a new class of receptor molecules known as sigma ligands to influence the origin or development of a disease."

ANAVEX 7-1037 More Effective in Pre-Clinical Studies

During pre-clinical studies, ANAVEX 7-1037 was administered directly into the abdominal cavity of immune-deficient mice at four different dose levels (100, 70, 40 and 10mg/kg). The mice had been inoculated subcutaneously with cancerous human cells on a "five days on, two days off" schedule. ANAVEX 7-1037 was administered beginning when tumors in advanced-stage subcutaneous mice models reached approximately 250 cubic millimeters in siz
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Anavex strengthens Board of Directors
2. Anavex advances drug candidate for treatment of Alzheimers disease
3. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
4. Drug Reduces Airway Mucus in Preclinical Asthma Model
5. Heavier hydrogen on the atomic scale reduces friction
6. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
7. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
8. Landfill mining reduces environmental impact of growing waste
9. Landfill mining reduces environmental impact of growing waste
10. First-Ever Cancer and Careers Seminar Debuts in Orange County
11. Assembly technique for tiny wires may eventually help detect cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... YORK, Feb. 28, 2012 Organovo, Inc., (OTCQB: ... on using its breakthrough NovoGen 3D human tissue ... research and medical applications, today announced that Keith Murphy, ... March 1st, 2012 TIME:   1:00 PM ...
... Calif., Feb. 28, 2012 Ultragenyx Pharmaceutical Inc., ... rare and ultra-rare genetic disorders, today announced that ... granted orphan drug designation for UX003 for the ... extremely rare autosomal recessive lysosomal storage disorder characterized ...
... Feb. 27, 2012 Ikaria, Inc., a critical care ... critically ill patients, today announced that it has enrolled ... investigating the use of inhaled nitric oxide (iNO) in ... commenced in December 2009, enrolled its last patient six ...
Cached Biology Technology:Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 2Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 3Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 4
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... June 13, 2012 To spread public knowledge of ... social media app which allows the general public to ... friends. Available free on iTunes ( http://itunes.apple.com/us/app/autism-quiz/id481913653?mt=8 ), ... for Android. Autism Quiz ...
... publication this week of a "map" of the bacterial make-up ... the ocean. Microbial communities that live on and in ... to have a critical role in human health and disease. ... ambitious Human Microbiome Project (HMP) to define the boundaries of ...
... announces the addition of a significant piece of ... Impact Test System (HITS) recently completed its final ... system is capable of producing horizontal impacts to ... distribution and in-use environments. "With the ...
Cached Biology News:More than 1 way to be healthy: Map of bacterial makeup of humans reveals microbial rare biosphere 2More than 1 way to be healthy: Map of bacterial makeup of humans reveals microbial rare biosphere 3Westpak Deploys Horizontal Impact Test System (HITS) 2
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
HSV-1 gE Envelope Protein (9H3)...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Biology Products: